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Abstract:
Over the past decades, statisticians and machine-learning researchers
have developed literally thousands of new tools for the reduction of high-
dimensional data in order to identify the variables most responsible for
a particular trait. These tools have applications in a plethora of settings,
including data analysis in the fields of business, education, forensics, and
biology (such as microarray, proteomics, brain imaging), to name a few.
In the present work, we focus our investigation on the limitations and
potential misuses of certain tools in the analysis of the benchmark colon
cancer data (2,000 variables; Alon et al., 1999) and the prostate cancer data
(6,033 variables; Efron, 2010, 2008). Our analysis demonstrates that models
that produce 100% accuracy measures often select different sets of genes
and cannot stand the scrutiny of parameter estimates and model stability.
Furthermore, we created a host of simulation datasets and “artificial
diseases” to evaluate the reliability of commonly used statistical and data
mining tools. We found that certain widely used models can classify the
data with 100% accuracy without using any of the variables responsible for
the disease. With moderate sample size and suitable pre-screening, stochas-
tic gradient boosting will be shown to be a superior model for gene selection
and variable screening from high-dimensional datasets.
Keywords and phrases: Casual inference, high-dimensionality, stochas-
tic gradient boosting, binary regression, Benjamini-Hochberg Fdr, support
vector machine, gene identification, variable selection.
1. Introduction
High-dimensional data is increasingly common in modern statistical analysis,
where the number of variables is on the order of thousands and beyond. In an
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international competition on the analysis of breast cancer, the raw data has p =
32, 670 bins for predictors (Hand, 2008). At the Center for Cancer Research, the
proteomic data for ovarian cancer has p = 360, 000 predictors and it is free for
anyone to download (http://home.ccr.cancer.gov/ncifdaproteomics/OvarianCD_PostQAQC.zip).
In a bankruptcy application, Foster and Stine (2004, JASA) used p = 67, 000
predictors in their model. Efron (2008, 2010) mentioned p = 6, 000 for microar-
ray gene expression data, p = 15, 445 for imaging processing, and p > 500, 000
for SNP analysis. In a different area of application, a New York Times article
(October 30, 2005) reported that Google utilizes millions of variables about its
users and advertisers in its predictive modeling to deliver the message to which
each user is most likely to respond. Furthermore, in the field of astrostatistical
applications, Efron (2008) mentioned p = 1010, which would dwarf other data
and is probably qualified to be called Mother of High-Dimensional Data.
In certain areas of predictive modeling with high-dimensional data, statistical
methods and machine-learning tools appear to be doing very well, but in other
applications where causal inferences are involved, the results are often less than
satisfactory. Shmueli (2010, Statistical Science) asked the question, “To Explain
or to Predict?”, and emphasized that “the type of uncertainty associated with
explanation is of a different nature than that associated with prediction” (a la
Helmer and Rescher, 1959). Here explanatory modeling refers to the statistical
analysis of cause-and-effect. The focus of our study is an extension of this effort.
For this purpose, we found that the field of gene identification provides an
excellent framework to discuss a number of issues related to the limitations and
potential misuses of causal inference from high-dimensional data.
The datasets in our study are taken from the field of microarray gene identi-
fication. This technology is a powerful tool for measuring the relative expression
level of thousands of genes in a single experiment. In particular, every cell in
an organism expresses its own set of genes. Skin cells express different genes
than bone cells, and colon cancer cells express different genes than normal colon
cells. Therefore, one way to determine what genes cause a particular trait or
disease is to compare the genes expressed in one cell type to those expressed in
the other cell type.
Microarrays allow this kind of comparative study to take place on a very
large scale: the expression level of thousands of genes can be compared across
cell types. In this study, our goal is to identify those genes that are differentially
expressed in cancer, as these differentially expressed genes may actually be the
cause of cancer formation and progression. In order to do this, the hundreds to
hundreds of thousands of data points collected in microarray experiments need
to be analyzed using sound and robust statistical methods.
Given the massive size of the datasets, and the number of statistical tech-
niques available for analysis, the field has attracted an enormous amount of
attention from researchers around the globe. A survey of the literature reveals
that there is a huge variety of techniques for selecting genes whose aberrant
expression correlates with a particular tissue type or disease state. These tech-
niques can be roughly grouped into the following two categories:
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• Multiple hypothesis testing that includes t-tests, the Bonferroni correction,
false discovery rates, empirical Bayes, Sidak method, Q-values, mid p-
values, platform p-value, F -test, two-step non-parametric statistical anal-
ysis, regularized t-test, hierarchical lognormal-normal model, etc. For ref-
erences, see for instance Leek and Storey (2011), Efron (2011, 2010, 2008),
Bar et al. (2010), Storey (2010), Ferreira1 and Zwinderman (2006), Du-
doit, Shaffer and Boldrick (2003), Sierra and Echeverria (2003), Guyon
and Elisseeff (2003), Benjamini and Hochberg (1995), etc.
• Statistical models and machine-learning methods that includes logistic
regression, ANOVA, support vector machines, neural networks, random
forests, k-nearest neighbors, diagonal linear discriminant analysis, na¨ıve
Bayes, nearest centroid, rough set, emerging pattern, a genetic-algorithm-
based Fisher’s discriminant analysis, Mahalanobis decorrelation, latent
class analysis, Laplace approximated EM microarray analysis, pathway
analysis, neighborhood mutual information, fuzzy mutual information, and
numerous other variations. For references, see for instance Huang et al.
(2011), Zuber and Strimmer (2011), Wang and Simon (2011), Bar et al.
(2010), Hu et al. (2010), Mongan et al. (2010), Cordell (2009), Lee et
al. (2008), Dean and Raftery (2008), Ma and Huang (2007), Guyon and
Elisseeff (2003), etc.
In addition, there are countless references within each of the above categories.
Furthermore, each technique in the above lists can have endless variations. For
instance,
• In their paper, “Should We Abandon the t-test in the Analysis of Gene
Expression Microarray Data,” Jeanmougin et al. (2010) considered eight
different tests representative of various modeling strategies in gene expres-
sion data: ANOVA (homoscedastic), Welch’s t-test (heteroscedastic), RVM
(homoscedastic), limma (homoscedastic and based on a Bayesian frame-
work) and SMVar (heteroscedastic and based on structural model), plus
two non-parametric approaches with the Wilcoxon’s test and the SAM
test.
• Regression-based methods would include sliced inverse regression, corre-
lated component regression, lasso regression, the elastic net, non-negative
garrote method, etc. Among these methods, in the area of lasso regres-
sion, there are nine different methods in a MATLAB toolbox by Liu et al.
(2009), and for each method one can define the penalty functions in multi-
ple ways to generate new models (http://www.public.asu.edu/~jye02/Software/SLEP/).
It is conceivable that one may find countless other variations in the liter-
ature.
• In the area of support vector machines (SVM), there are at least 25 dif-
ferent kernels
(http://crsouza.blogspot.com/2010/03/kernel-functions-for-machine-learning.html).
With some modifications and hybridizations, it would be straightforward
to generate hundreds of additional kernels without knowing which one is
best suited to analyze the data at hand.
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• The well-known CART method, classification and regression tree, as laid
out in Breiman, Friedman, Olshen, and Stone (1983) has endless varia-
tions in the machine-leaning literature including Gini index, chi-square
criterion, entropy, genetic-algorithm tree (Cha and Tappert, 2009), and
neural-network tree (SAS, 2003). The techniques can easily fill up a huge
volume to greet a biologist or to send him/her down the wrong path when
it comes to analyzing a high-dimensional dataset.
• Neural Network models have even more variations than CART: multilayer
perceptrons (MLPs), radial basis function (RBF) networks, and many
other forms of network architectures. SAS, a software package, provides
nine different kinds of architectures, fourteen different kinds of error func-
tions, eight different kinds of combination functions, and twelve different
kinds of activation functions. There are a lot more in scholarly publica-
tions (see e.g., a 2009 book by Pereira and Rao titled, Data Mining using
Neural Networks: A Guide for Statisticians). A Google search of “neural
network architecture” (with quotations marks) rendered 3,130,000 results,
with more coming every day.
The situation reminds us the famous example from 1972 where 10,465 tech-
niques were constructed in the estimation of a statistical quantity called the
location parameter (Stigler, 2010, a la Andrews et al., 1972). For the modern-
day gene hunt, the number of techniques available is equally endless.
A natural question is: how reliable are these statistical tests and modeling
techniques? Specifically, one may ask whether the models are stable, whether
they are consistent, and whether it is true that “the increased level of algorithmic
complexity does not always translate to improved biological understanding”
(Mongan et al., 2010). Along the same line of inquiry, Wang and Simon (2011,
p. 22, Table 5) found that many tools achieved high prediction accuracies, yet
did so using different important genes for the same disease. In an earlier study,
Efron (2008, p. 7) pointed out that
The prostate data has E(Fdr) = 0.68, indicating low power [here E(Fdr) = the
expected value of false discovery rate]. If the whole study were rerun, we could
expect a different list of 50 likely nonnull genes, barely overlapping with the first
list.
In short, the scientific literature focused on the identification of relevant genes
from microarray data is vast and not necessarily reliable. Consequently, the main
objective of this article is to evaluate some widely-used statistical tests and
machine-learning approaches in the analysis of microarray data. Specifically, we
look at two microarray datasets (detailed below) and we generate sets of simu-
lated microarray data for which the genes that contribute to the diseased state
are known. We employed several well-known statistical methods to identify the
differentially expressed (important) genes and classify the datasets. Based on the
results for the experimental and simulated datasets, we make recommendations
on the statistical methods we find to be the most reliable.
Our study was motivated by two datasets that are widely known in the field
of cancer research:
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• Colon cancer from Alon et al., (1999). The data consists of 2,000 genes
and 62 patients, 40 who have colon cancer, and 22 who do not.
• Prostate cancer from Singh et al. (2002). The data consists of 6,033 genes
and 102 patients, 52 who have cancer and 50 who are healthy.
In Section 2, we review previous results from the colon cancer data and then
present new results on other models that outperform the original results in terms
of accuracy and the number of genes selected. Furthermore, we discuss the merits
and potential pitfalls of the top models we tested on both the colon and prostate
cancer data, cautioning that even the results from these top models may be
deceiving under certain conditions. In Section 3, the top models undergo further
scrutiny when we test their performance in a variety of scenarios using simulated
data. The results of analyzing the simulated data further strengthen our belief
that several popular models may mislead investigators analyzing microarray
data. In Section 4, the relationship between sample size, number of genes and
statistical reliability is explored in depth. Our analysis suggests that gradient
boosting is a significantly better tool than the others explored, and that the
sample size used in some microarray experiments is not sufficiently large for most
statistical methods to accurately and consistently select the most important
genes to classify the data.
2. The Reliability of Statistical Methods (I): Results from Real
Datasets
2.1. Three Statistical Methods for Analyzing Microarray Data
In this Section, we review previous statistical analyses of the colon cancer
dataset. We then compare the performances of our models with these previously-
published results. Much to our delight, some of our models achieved 100% accu-
racy in classifying the data in multiple runs with different random splits of the
data into training and validation purposes. In addition, our models achieved this
accuracy using fewer genes than most previously-published analyses. However,
our further investigations indicate that the models are not reliable, as will be
seen in the subsequent discussions.
Table 1 (see next page) presents a brief summary of the previous analysis of
the colon cancer dataset. We note that the models attempt to classify a sample
as cancerous or normal using anywhere from 5 to 2,000 genes, and the error
rates range from 11.3% to 34%.
The first statistical method we used to analyze the colon cancer microarray
data was that of partial least squares (PLS) with leave-one-out cross-validation.
Here leave-one-out means that, given n observations, the model was trained
using n−1 data points, and the model was used to predict whether the remaining
data is representative of cancer or no cancer. The model was run n times by
altering which n − 1 of the n data points were used for training, and which
dataset was being classified as cancerous or normal based on the trained model.
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Table 1
A brief summary of the journal results on the colon cancer data.
Variable # of Genes Prediction
Selection Selected Error
Blind Bet (No Model) - - 2000 33%
Alon et al. (1999)
Proc. Natl. Acad. Sci clustering 500 n/a
Weston et al. (2001)
Adv Neural Informat SVM 15 11.4%
Guyon et al. (2002)
Machine Learning SVM 8 34%
Weston et al. (2003)
J. Machine Learning kernel methods 20 13.7%
Su et al. (2002)
Bioinformatics t-tests, SVM 100 n/a
Do et al. (2005)
J. Royal Stat Soc. Fdr 1938 n/a
Ma et al. (2007)
BMC Bioinformatics Lasso 19 12.9%
Lee et al. (2008)
J. Biopharmaceut. Stat SVM (1-norm) 8 11.3%∗
Lee et al. (2008)
J. Biopharmaceut. Stat SVM (IFFS) 5 11.3%∗
Bar et al. (2010)
Statistical Science Laplace EM 61 n/a
Quite impressively, when PLS selected the nine most important genes, the leave-
one-out prediction error was 0% (Table 2, see next page). This indicates that
the model could always correctly classify the one microarray dataset that was
not used for training purposes.
Before running the PLS models to get the data shown in Table 2, the original
2,000 genes in the dataset were prescreened by an R-square variable selection
procedure which selected only 25 genes from the larger pool. The R-square
procedure is one of many prescreening techniques available for reducing the di-
mensionality of a dataset before searching for the most important genes (Guyon
and Elisseeff, 2003). This prescreening procedure is essential, as PLS does not
perform reliably using thousands of predictors at a time. The genes that were
selected from the R-square variable selection procedure are then used in the
subsequent runs of the partial least squares model. The default PLS with 25
genes achieved 0% error rate, meaning it always correctly classified whether the
remaining data set represented cancer or no cancer. We then used a stepwise
elimination process to cut the low-ranking genes from the model. We found that
the 16 lowest-ranking genes of the 25 prescreened genes could be eliminated from
the model without impacting predictions: that is, using only the 9 genes whose
expression varies the most between cancer and no cancer, the error rate of PLS
is 0%. However, if we cut down to the top 8 genes, the error rate went up slightly
to 3.2%.
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Table 2
PLS achieved 0% error rate on the colon cancer data with 9 genes (PLS-1). If we cut the
least important gene from the list of 9 to get 8 genes (PLS-2), the error rate goes up to
3.2%, still significantly better than those in Table 1.
# of Genes Leave-One-Out
Selected Prediction Error
PLS-1 9 0%
PLS-2 8 3.2%
The next statistical methods we utilized to analyze the colon cancer data
are that of logistic regression and neutral networks (NN), both of which require
variable prescreening similar to PLS. Our regression and neural network analyses
are based on random splits of the data into a training set (75% of the data) and
validation set (25% of the data). The results of analyzing the colon cancer data
using these statistical methods are displayed in Table 3.
Table 3
A comparison of model performances with backward elimination (training data: 75%,
validation data: 25%).
# of Training Validation
Genes Error Rate Error Rate
Regression-1 13 0% 0%
Regression-2 12 0% 5.9%
PLS-3 13 0% 0%
PLS-4 12 0% 5.9%
Neural Network-1 19 0% 0%
Neural Network-2 18 4.3% 13.3%
From Tables 2 and 3, the best model appears to be PLS-1 with 9 genes and
0% leave-one-out error rate. While the error rate is the same as achieved for
other statistical methods, we say PLS-1 appears to be the best model as it
required the fewest number of genes to classify the data with a 0% error rate.
In order to facilitate comparison with regression and neural networks, partial
least squares was also conducted by placing 75% of the data in the training set,
and 25% in the validation set. PLS-3 is the analysis when 13 genes were selected
via this split of the data, and PLS-4 is the analysis when 12 genes were selected
via this split of the data. Notice that when compared to regression and neural
networks, PLS with 13 genes does just as well as regression with 13 genes and
neural networks with 19 genes. Notice, however, that when the data is split up
in this manner, PLS requires more than 9 genes to achieve a 0% error rate.
While the low error rates we have obtained are desirable, this does not demon-
strate that the statistical methods are consistently classifying the data. For in-
stance, it is plausible that each method uses a very different set of genes to
achieve the low classification error rates. In order to explore the between-model
consistency, we looked at the top genes selected by partial least squares, regres-
sion and the neural network (Table 4). In each case, an R-square prescreening
method was applied to reduce the number of genes input into the statistical
methods from 2,000 to 38. Fortunately, the three models appear to be very con-
sistent: seven genes are selected by all three statistical methods, and three genes
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are selected by at least two statistical methods. Every gene selected by PLS-1
was also selected by one or both of the other statistical methods.
Table 4
Top genes selected by the three different models. The seven common genes in the three
models are indicated with a *. The two genes common to regression and PLS are indicated
with a †, and the one gene common to regression and neural network is indicated with a #.
Regression PLS-1 Neural Network
Accuracy = 100% Accuracy = 100% Accuracy = 100%
1 Gene-1025 Gene-1769∗ Gene-1769∗
2 Gene-1231∗ Gene-1466† Gene-1231∗
3 Gene-1351∗ Gene-1367∗ Gene-1421
4 Gene-1367∗ Gene-1482† Gene-1702
5 Gene-1466† Gene-419∗ Gene-1351∗
6 Gene-1482† Gene-1351∗ Gene-258
7 Gene-1644∗ Gene-1644∗ Gene-1644∗
8 Gene-1769∗ Gene-249∗ Gene-1475
9 Gene-1895# Gene-1231∗ Gene-1895#
10 Gene-249∗ Gene-419∗
11 Gene-419∗ Gene-1914
12 Gene-580 Gene-1367∗
13 Gene-662 Gene-1889
14 Gene-945
15 Gene-249∗
Having checked for consistency among the statistical methods, we next sought
to ensure that the way the data was being partitioned does not bias the results.
To undertake this analysis, we used five different random seeds to split the data
into the training set and the validation set. We found that independent of which
datasets were placed in the training set and which were placed in the validation
set, the number of genes required to achieve a 0% validation error rate were
rather consistent for each statistical method, as shown in Table 5.
Table 5
Five runs of neural network on the colon cancer data with different seeds, using the same 19
prescreened genes. In five runs, all neural network trials have 0% error rate.
Seed Schwarz Training Validation
Bayesian Criterion Error Rate Error Rate
1 178.146 0% 0%
2 178.159 0% 0%
3 178.156 0% 0%
4 178.178 0% 0%
5 178.148 0% 0%
2.2. Vetting of the Statistical Methods: Should we Believe What we
See?
Taken at face value, our results appear very encouraging in the sense that three
different models, PLS, regression and neural network, achieved 0% prediction
error. Table 4 also showed that the three models select seven common genes and
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are very consistent. But subsequent analysis in Sections 2.2, 2.3, 3.2, 3.3 will
cast doubt on conclusions drawn from these models.
First of all, from Table 6, we observe that the estimates of the logistic re-
gression model are relatively small while the corresponding standard errors of
the estimates are quite large. As a result, the corresponding Wald chi-squares
are also very small and the p-values are not significant. Thus, any conclusions
drawn from the model are dubious and may not generalize well for new data.
Table 6
Parameter estimates of the regression model. The estimates are very small while the
corresponding standard errors of the estimates are very large.
Gene Estimate Standard Error Wald Chi-Square Pr>ChiSq
1025 0.00608 0.0475 0.02 0.898
1231 0.1188 0.4193 0.08 0.777
1351 0.0203 0.1179 0.03 0.8631
1367 -0.06 0.2638 0.05 0.8202
1466 -0.0349 0.4738 0.01 0.9413
1482 0.0258 0.3734 0 0.9449
1644 0.0523 0.29 0.03 0.857
1769 -0.1642 0.5339 0.09 0.7584
1895 -0.00606 0.0785 0.01 0.9385
249 0.00391 0.0111 0.12 0.7249
419 0.04 0.1262 0.1 0.751
580 -0.0267 0.1666 0.03 0.8726
662 -0.0103 0.0406 0.06 0.799
The problem is related to “complete separation” in binary regression where
the maximum likelihood function does not exist and the iterations do not con-
verge. As a result, the model, albeit with 0% error rates in multiple runs on
different seeds, may not hold up to future observations. A discussion of this
phenomenon can be found at http://www.ats.ucla.edu/stat/sas/library/logistic.pdf. An-
other reference on the convergence of the maximum likelihood estimate is in
Stokes (2004). Potential ways to fix this problem for logistic regression have
been proposed; see, e.g., Firth (1993), Heinze and Schemper (2002), and Park
and Hastie (2008).
Next, we considered the parameter estimates of PLS as shown in Table 7.
Table 7
Parameter estimates of the PLS model. Standardized Parameter Estimates are very small
so this model may not generalize well to new data.
Gene Standardized Parameter Rejected by Parameter
Estimate Estimate?
1769 -0.69336 No
1466 -0.31386 No
1367 -0.29207 No
1482 0.1661 No
419 0.30232 No
1351 0.3035 No
1644 0.37666 No
249 0.45373 No
1231 0.50063 No
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The traditional cutoff z-value for statistical significance in the Standardized
Parameter Estimates are values outside ±1.96. However, In Table 7, all of the
genes selected fail to cross this significance threshold. In practice, users often do
not know whether the parameter estimators are normally distributed and cutoff
values of 0.1 or 0.2 are often used for the standardized estimates. In Table 7,
the cutoff is 0.1 and it renders a model with 100% prediction accuracy.
We now turn our attention to the reliability of the neural network predictions.
To do this, we will limit our model to a structure with only one hidden unit to
facilitate the comparison of parameter estimates. Table 8 below shows some of
the top predictors selected by the neural network.
Table 8
Top predictors selected by the neural network.
Gene Weight
(Ranked by Absolute Value)
1769 -2.866915264
1231 2.634994782
1421 -2.243876759
1702 -1.999461292
1351 1.722926448
258 -1.650588414
1644 1.530640588
1475 1.401072018
1895 -1.107656933
419 1.002626559
Note that in Table 8, the selection of the top genes is rather subjective and
the cutoff is arbitrary. In practice, one can try backward elimination, forward
inclusion, and the stepwise procedure to select the genes. However, unlike PLS
and regression, the literature contains no reliable ways to calculate the standard
error of the weight and hence there is no way to judge whether the estimates of
the weights would behave like those in Table 7 (PLS) and Table 6 (regression).
The same can be said for SVM (support vector machines) and other methods
in Table 1.
In conclusion, a regression model or PLS can achieve 100% accuracy but the
parameter estimates are not reliable. In the current literature, the problem of
“complete separation” of logistic regression is well-known, but there is no such
analysis for PLS, neural networks, support vector machines, or other models. In
the next section, we provide further proof that models with high accuracy can
be very misleading.
2.3. Analysis of Prostate Cancer Data: More Miracles or More
Illusions?
We will now shift our focus from the colon cancer dataset to the benchmark
prostate cancer data that has 102 patients (52 cancer, 50 normal) and 6,033
genes. The data was collected and analyzed by a team of 15 scientists from a
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dozen institutions including HarvardMedical School, Whitehead Institute/Massachusetts
Institute of Technology, and Bristol-Myers Squibb Inc. Princeton.
As one would imagine, it is very expensive to conduct a microarray experi-
ment of this magnitude, and it would be desirable to have more cost-effective
alternatives. As a result, we frame up a scenario as follows: a biologist who has a
limited budget collected only 10% of the samples as compared to the benchmark
dataset (i.e., there are only 10 patients in the sample). The biologist pre-screened
the 6,033 genes by a statistical variable selection technique, then ran the PLS
model with leave-one-out cross-validation, and found that the model can clas-
sify the validation datasets as cancer or normal with 100% prediction accuracy.
In addition, the biologist used regression to double check the PLS results and
also obtained 100% prediction accuracy with the same genes as the PLS model:
Gene1149, Gene4201, and Gene4780. Finally, the biologist double-checked the
statistical results by examining the posterior probabilities as shown in Table 9.
Table 9
PLS posterior probabilities of the 10 patients using leave-one-out cross-validation.
Patient Mean Posterior Probability Cancer or Normal?
1 1 Cancer
2 1 Cancer
3 0.998 Cancer
4 0.995 Cancer
5 0.979 Cancer
6 0.011 Normal
7 0.007 Normal
8 0.005 Normal
9 0 Normal
10 0 Normal
The posterior probabilities indicate that the model did extremely well clas-
sifying the data. This would represent an excellent finding for the biologist,
especially considering that regression and PLS use different methodologies: re-
gression is based on the maximum likelihood estimation of the parameters of
the following equation:
log
(
p
1− p
)
= a+ b1x1 + b2x2 + · · ·+ bkxk + ε,
while PLS is based on the extraction of latent variables from the covariance
matrices of
X ′X and Y ′X.
Since the two methodologies are vastly different, the results appear to have
reinforced each other in a significant manner. The scientist also noticed that
PLS has been widely used in analytic chemistry (see, e.g., Wold et al., 2001)
and other fields (see, e.g., Vinzi et al., 2010), so the results are very encouraging
and the 10% sample has the potential to cut research costs by 90%. If the results
hold water, it would be great news for all researchers in this field of study.
But now the problem: three other imaginary scientists did the same experi-
ment with a different 10% of the sample. The situation is depicted in the process
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flow shown in Figure 1.
Fig 1. Process flow of the PLS and regression models with a mere 10% sample of the prostate
cancer data. Here four scientists used different samples to run their models. The first and the
last scientists also used regression to double check their PLS results.
Now the miracle (see Table 10 below): the four scientists all achieved 100%
prediction accuracy but the genes they selected are vastly different.
Table 10
Four different runs of PLS using leave-one-out cross validation all achieved 100% accuracy
but the genes they selected are vastly different. Furthermore, the genes selected by PLS have
no overlap with the genes selected by Efrons 2010 study.
Method Prediction Genes Selected Sample Seed
Accuracy Size
PLS-e1 100% 1149, 4201, 4780 10 12345
PLS-e2 100% 38, 476, 5585 10 23451
PLS-e3 100% 1352, 1751, 3560 10 34512
PLS-e4 100% 38, 1871 10 45123
Efron n/a 610, 1720, 332, 364, 102 n/a
(2010) 914, 3940, 4546, 1068, 579, 4331
Table 10 also includes the 10 genes that were selected by Efron (2010) which
have very little in common with the rest four sets of the genes. In summary, four
scientists set out to collect data and use PLS to find the most important genes.
In two of the four cases, the biologists even confirmed their PLS predictions
using regression. Each of their models has a 100% prediction accuracy, but the
genes they picked are vastly different. Which set of genes would you believe?
We conclude that the 100% prediction accuracy actually misled our imaginary
scientists to believe that a sample size of only 10 patients is sufficient to analyze
the prostate cancer dataset.
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3. THE RELIABILITY OF STATISTICAL METHODS (II):
RESULTS FROM SIMULATION DATA
In this section, we will create our own data to simulate microarray data. Compa-
rable to the colon cancer dataset, the simulated data will contain the expression
level of 2,000 “genes” for 62 simulated “patients”. In the colon cancer dataset,
more than 15 of the genes are correlated with a correlation coefficient r > 0.7
(see the scatterplot of Gene493 and Gene249 in Figure 2).
Fig 2. The scatterplot of the non-normalized expression levels of Gene493 and Gene249 from
the colon cancer data. The correlation of these two variables is 0.8151 with p ∼= 0.0000.
As a result, we added correlations to the three genes X1, X2, X3 in our simulation
data. From this point forward, Xi represents the numerical gene expression level
of gene Xi. The other 1,997 gene expression levels are generated from a uniform
distribution.
The corresponding formulae for generating correlated X1, X2 and X3 are as
follows. Assume X1, Z1, and Z2 are independent and identically distributed
random variables. Let
X2 = X1 + bZ1
X3 = X2 + cZ2.
Using b=0.8 and c=0.75 gives the following correlations between X1, X2 and
X3:
ρ(X1, X2) =
σ2(X1)
σ(X1)
√
σ2(X1) + b2σ2(Z)
=
σ2(X1)
σ2(X1)
√
1 + b2
=
1√
1 + b2
∼= 0.78,
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ρ(X1, X3) =
1√
1 + b2 + c2
∼= 0.67,
ρ(X2, X3) =
√
1 + b2√
1 + b2 + c2
∼= 0.86.
The correlations of the three predictors in the simulation data are shown in
Figure 3.
Fig 3. The scatterplots and the correlations among X1, X2, and X3.
To facilitate the simulations of 5-gene and 10-gene interactions, we re-scaled
the ranges of the variables. The mean, standard deviation, maximum, and min-
imum values of X1, X2, X3 are listed in Table 11.
Table 11
Mean, standard deviation and range of genes X1, X2, X3 when n = 62.
Gene Mean Standard Deviation Minimum Maximum
X1 43.9 26.4 0.4 97.2
X2 166.3 67.2 23.5 283
X3 278.3 92.4 35.2 481.3
We will use this controlled dataset to represent the gene expression level
of 62 patients. Then, we will define functions that classify the 62 patients as
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cancerous or normal. This will allow us to examine how the various statistical
methods perform at classifying the simulated data as diseased or normal. The
advantage of this approach is that we already know how each dataset should
be classified, and we also know which gene expression levels are responsible for
that classification of the disease.
There is precedent for using simulated data to rigorously examine the relia-
bility of a statistical model. For instance, Park and Hastie (2008) investigated
gene-gene and gene-environment interactions using three discrete epistatic mod-
els and a heterogeneity model of two interacting genes. Each of the two genes is
assumed to have a dominant allele (form) and a recessive allele, and the models
captured different potential modes of interaction between the two genes. Noisy
data was generated from each of these models, and statistical methods along
with multifactor dimensionality reduction were used to train and classify the
simulated datasets.
What Park and Hastie did was model the interaction between the two genes of
interest in their study (2008). However, in the case of microarray data, there are
potentially thousands of interacting genes. This greatly complicates the analysis
of microarray data, as the scale makes it nearly impossible to model the gene-
gene interactions. To put this in perspective, Cordell (2009, Nature Reviews
Genetics) wrote an extensive review on detecting gene-gene interactions that
underlie human disease. The review discussed different methods for decipher-
ing all two-locus interactions and the associated computational costs of each
method. The article concluded “an exhaustive search of all three-way, four-way
or higher-level interactions seems impractical in a genome-wide setting.” This
point was driven further home in a recent article by Van Steen entitled “Trav-
elling the world of gene-gene interactions” (2011, Briefings in Bioinformatics).
Given this reality, we cannot expect to build models that will accurately capture
the interaction between all genes that give rise to cancer. Therefore, we cannot
build a discrete, allele-based model comparable to that of Park and Hastie for
our purposes. Instead, we will have to generate expression-level datasets that
are comparable to datasets generated from microarray experiments. We then
need mathematical equations that can classify the dataset as diseased or nor-
mal based on the expression level of a hand-selected set of genes.
3.1. The Simulated Diseases
In order to classify our simulated datasets, we have designed equations that
take the dataset as input, and output whether the dataset represents a diseased
state or a normal state. We start with a disease in which only a single gene is
responsible for the disease, and we build up from there adding more contributing
genes, and more complex (nonlinear) interactions between the genes.
Our simulated dataset consists of 2,000 genes/predictors (X1-X2000) for 62
“patients” and eight initial equations that will be used to classify the simulated
patients as diseased or normal. In the first three disease equations, each gene
linearly contributes to the disease state, and there are no gene-gene interactions.
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• Disease1: disease or normal is determined solely by the expression level
of X1:
f1 =
{
0, if X1 > 53.1
1, otherwise
where 0 represents a normal dataset and 1 represents a diseased dataset.
This is similar to a number of single gene diseases, including hemophilia
A (X-linked recessive disease determined by F8 gene), cystic fibrosis (au-
tosomal recessive disease determined by CFTR gene), sickle-cell anemia
(autosomal recessive disease determined by HBB gene) and Huntington’s
disease (autosomal dominant disease determined by HTT gene) to name
a few (Chial, 2008).
• Disease2: disease or normal is determined by a linear combination of X1,
X2:
f2 =
{
0, if 2X1 +X2 > c2
1, otherwise.
This is similar to the familial breast cancer, which is attributed to two
genes: BRCA1 and BRCA2 (Ritchie et al., 2001). Note that familial breast
cancer is rare (about 5% of the female population). For the non-familial
breast cancer, the genetic structure is a lot more complicated.
• Disease3: disease or normal is determined by a linear combination of X1,
X2, X3:
f3 =
{
0, if 2X1 + 0.7X2 + 1.5X3 > c3
1, otherwise.
Both colon cancer and prostate cancer involve more than three genes (see,
e.g., Table 1 and Table 10). Our analysis will start with three genes and
gradually move upward.
The cutoff value in each function was designed so that the distribution of
the disease is relatively balanced as shown in the colon cancer and prostate
cancer data. For instance, the Disease 1 function f1 used a cutoff of 53.1 to
keep the number of cancer and normal patients from being heavily skewed in
either direction. Figure 4 displays the histograms of diseased and normal cases
using Disease1 and Disease2. In the remaining diseases, the cutoffs were simi-
larly chosen so that the distribution of disease is relatively balanced. Instead of
presenting the exact cutoff value in the other diseases, we will simply use ci to
represent the cutoff chosen for disease i.
C. Wang et al./Casual Inference from High-Dimensional Data 17
Fig 4. The distributions of the Disease1 and Disease2 are relatively balanced, with 1 indicating
cancer, and 0 indicating normal.
In each of Disease1 through Disease3, only linear combinations of different
genes are considered, so no gene-gene interactions take place, and each gene
contributes independently to the disease state. Disease4 through Disease8 each
account for nonlinear contributions of genes, and gene-gene interactions.
• Disease4 is determined by a nonlinear combination of three genes (X1,
X2 and X3) with the nonlinear term in X1:
f4 =
{
1, if X2
1
+X2 +X3 > c4
0, otherwise.
This represents a scenario in which X1 is a stronger determinant of the
disease than X2 or X3.
• Disease5 is a modification of Disease4 where X1, X2 and X3 are centered
around their means (µi is the mean of gene Xi):
f5 =
{
1, if (X1 − µ1)2 + (X2 − µ2) + (X3 − µ3) > c5
0, otherwise.
• Disease6 is similar to Disease4, except there is a nonlinear term for both
the expression level of X1 and X2:
f6 =
{
1, if X21 +X
2
2 +X3 > c6
0, otherwise.
• Disease7 is determined by a nonlinear combination of three genes:
f7 =
{
1, if X1X2 +X2X3 +X1X3 > c7
0, otherwise.
In this case, all gene interaction occurs in a pair-wise fashion. The effect
of each gene individually is not considered.
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• Diseas8 is determined by a nonlinear combination of three genes:
f8 =
{
1, if X1X2X3 > c8
0, otherwise.
In this case, all three genes interact and mutations in a single gene, or
even two genes, have no independent effect on the disease state.
3.2. Machine-Learning and Predictive Modeling of Simulated
Diseases
In their ground-breaking paper in Cancer Cell, Singh et al. (2002) used K-
nearest neighbor for binary classification and obtained 90% accuracy in the
prediction of prostate cancer. Furthermore, they maintained that (p. 206):
The successful prediction of patient outcome will ultimately lead to improved
decision making regarding current therapeutic options and the rational selection
of patients at high risk for relapse for clinical trials testing adjuvant therapeutics.
We agree with this statement. But a cautionary note is that certain predictive
models may produce 100% accuracy yet pick only irrelevant genes ; that is, genes
that are not implicated in the disease state (see results of Disease5 below). We
summarize our findings in Tables 12 and 13.
Table 12
Gene selections and error rates of various models when n = 62 patients. Bold-faced genes
indicate when the model captured all the important genes. “. . .” indicates a set of irrelevant
genes.
Disease1 Disease2 Disease3 Disease4
True Genes X1 X1, X2 X1, X2, X3 X1, X2, X3
Interaction Linear Linear Linear Nonlinear
Type X1: most
important
Genes selected by model
(error rate)
Decision Tree X1 X1, X2 X1, X2 X1
(0%) (1.6%) (4.8%) (0%)
Boosting X1 X1, X2 , . . . X1, X2, X3 , . . . X1
(0%) (0%) (0%) (0%)
PLS X1 , X666 X1, X2 X1, X3, X1009 X1 , . . .
(0%) (3.3%) (3.2%) (0%)
NN X1 , . . . X1, X2 , X1025 X1, X3, . . . X1 ,. . .
(0%) (0%) (5.6%) (11.8%)
Reg-stepwise None X2 X1, X540 None
(6.3%) (27.8%)
Regression default X1 X1, X2 , . . . X3, . . . X1
(0%) (0%) (5.9%) (0%)
For the linear diseases 1 and 2, each model with the exception of stepwise
regression did an excellent job classifying the data. The statistical methods each
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identified the genes that contribute to the disease state, and classify the data
with at least 96% accuracy. While some of the statistical methods identified
genes that were not implicated in the disease state, these false discoveries are
much less worrisome to biologists than false non-discoveries. For Disease 3, only
gradient boosting selected all of the important genes.
Disease 4 is the first nonlinear disease we examined. In the formula to com-
pute Disease4, the expression level of X1 is squared, meaning it represents the
most important gene, with X2 and X3 being less influential. This may be the rea-
son that three models (decision tree, gradient boosting, and regression) picked
up only X1 and subsequently had a 0% error rate. While identifying all con-
tributing genes is most desirable, identifying the major contributing gene is most
important from a biological perspective, so these three methods can adequately
handle Disease4.
Table 13
Gene selections and error rates of various models for n = 62 patients. Bold-faced genes
indicate when the model captured all the important genes.
Disease5 Disease6 Disease7 Disease8
True Genes X1, X2, X3 X1, X2, X3 X1, X2, X3 X1, X2, X3
Interaction Nonlinear No Interaction Nonlinear Nonlinear
Type X1 is the most X1, X2: more 2-way interaction 3-way interaction
important important
Genes selected by model
(error rate)
Decision X1 X2 X2, . . . X1, X2
Tree (0%) (3.2%) (3.2%) (4.8%)
Boosting X1 , . . . X1, X2 X3, X10 X1, X2, . . .
(11.8%) (0%) (11.8%) (11.8%)
PLS irrelevant genes none X2, X3, . . . X1, X2
(0%) (0%) (9.7%)
NN irrelevant genes . . . X2, X3, . . . X1, X2, . . .
(5.9%) (44.4%) (0%) (0%)
Reg- irrelevant genes X2 X2, X616 X1, X2
stepwise (29.4%) (11.1%) (23.5%) (5.9%)
Reg-default irrelevant genes . . . X2, . . . X1, X2
(0%) (44.4%) (3.2%) (4.8%)
LASSO irrelevant genes X1, X2 X2, X3, X1, X2,
(0%) (0%) . . . (0%) . . . (0%)
Turning our attention to nonlinear diseases with gene interactions, we begin to
notice the statistical methods have difficultly identifying all contributing genes
(Table 13). While there are several statistical methods for Disease6 through
Disease8 that can identify two of the three contributing genes, there is not
a single statistical model that correctly identifies all three relevant genes for
Disease7 or Disease8. In subsequent analysis, we will show that with an increase
of sample size from n = 62 to 102, Boosting can do very well with 3-gene
interactions. For higher-order interactions (5 genes or 10 genes), we will show
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that larger samples are needed.
Disease5 (first column of Table 13) gave another surprising result. Here PLS,
LASSO, and default regression achieved 0% error rates, but the genes they
picked are purely irrelevant. This raises a red flag: how can the statistical meth-
ods achieve 0% error rates when the genes that determined the disease state are
not even being considered?
Note that the results of LASSO is compatible with the findings in a forthcom-
ing Statistical Science article (Huang et al., p. 14-15): LASSO “selects 17 genes
out of 30 and 435 markers out of 532, failing to shed light on the most important
genetic markers,” http://www.imstat.org/sts/future_papers.html. Here we used the least
angle regression with 5-fold cross-validation to run LASSO. The results are not
very encouraging.
Fortunately, both decision tree and gradient boosting were able to correctly
identify X1 as the major contributor of Disease5, though they were unable to get
the minor contributors. In fact, in two clean cuts, decision tree faithfully picks
X1 with 100% prediction accuracy using leave-one-out cross-validation (Figure
5). This stands in stark comparison to other popular models like regression and
neural network, which select all irrelevant genes. This is an indication that the
tree family methods (decision tree and boosting) may be better at detecting the
underlying structure of the gene interactions.
Fig 5. While popular models such as neural network, PLS, and regression selected irrelevant
genes with 100% prediction accuracy, the decision tree was able to pick the correct variable
in two cuts. The three end-nodes of the tree show 100% prediction accuracy in binary classi-
fication.
A related note is that Disease5 is not representative of any known disease
in the sense that there is no biological basis to support the centering of the
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variables around their means. The centering created the following histograms
for cancer (right panel, Figure 6) and normal patients (left panel, Figure 6):
Fig 6. The right panel has a big gap in the middle of the histogram and is unlikely to represent
any biological disease; instead, it is a “statistical disease” which causes certain models to select
irrelevant genes with 100% classification accuracy.
In Figure 6, The histogram on the right has a big gap in the middle and is
unlikely to happen for cancer or any biological diseases; instead, it is a “sta-
tistical disease” which causes three popular models (neural network, PLS, and
regression) to select irrelevant variables with 100% classification accuracy. We
believe there are many other statistical diseases like the one presented here.
With time and effort, we may found more examples to expose the weaknesses
of statistical models that would ultimately strengthen the science of statistical
disciplines.
A final detail about Disease1 through Disease8 is that we generated our
own data so that the numbers of cancer and non-cancer patients are relatively
balanced. In reality, this is not the case. In some scenarios, we tried to create
1,000 patients, where 97% are normal and 3% have cancer. The data is lopsided
and none of the models we tried were able to handle it. Consequently, we used
an oversampling technique to select all cancer patients and an equal number of
normal patients. The oversampling process did work well, and gave results that
are similar to what we have in this Section.
4. SAMPLE SIZE
In Section 3, the simulation datasets were motivated by the colon cancer bench-
mark data which has 62 patients and 2,000 genes. At this sample size, there
were several statistical methods that worked well when a linear combination of
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genes caused the disease. However, the models did not work well with nonlinear
interactions of three genes. In this section, we study the effect of both sample
size and the number of contributing genes on the reliability and accuracy of
several statistical models.
4.1. Three important genes, 102 patients
Recall that in Section 3.2, when there are only three important genes implicated
in the simulated disease, certain models did well with linear equations (Disease1
through Disease4) but not so for the nonlinear equations with gene-interactions
(n = 62). In this section we increase the sample size from n = 62 to n= 102
(with n = 102 being motivated by the prostate cancer dataset), and consider
Disease6 through Disease8 as defined in Section 3. With this moderate increase
of sample size, gradient boosting picks all important genes and its prediction
accuracies range from 93% to 100% as shown in Table 14 below. In Table 14,
we also include a semi-saturated nonlinear three gene model:
f9 =
{
1, if X1 +X2 +X3 +X1X2 +X2X3 +X3X1 +X1X2X3 > c9
0, otherwise
Table 14
Gradient boosting picks all important genes with 3-gene nonlinear relationships and n = 102
patients, while decision tree does not.
Disease5 Disease6 Disease7 Disease8
True X1, X2, X3 X1, X2, X3 X1, X2, X3 X1, X2, X3
Genes No Interaction 2nd order 3rd order 3rd order
X1, X2: more interaction interaction interaction
important semi-saturated
Genes selected by model
(error rate)
Decision X1, X2 X2, X3 X2 X2
Tree (7.1%) (2.5%) (2.9%) (3%)
Gradient X1, X2, X3 X1, X2, X3 X1, X2, X3 X1, X2, X3
Boosting (5.9%) (6.7%) (6.7%) (6.7%)
Recall that gradient boosting did not perform well on Disease7 and Disease8
when n = 62 patients (Table 13). Table 14 above shows that if n = 102 patients,
then the model picks all the important genes with high prediction accuracy, and
it even gets the relevant minor contributing genes (see Disease6 in Table 14).
4.2. Five important genes, 102 or 204 patients
In this section we go further to include 5 important genes in the simulation
study:
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f10 =
{
1, if Π5i=1Xi > c10
0, otherwise
Table 15 below summarizes the results with gradient boosting and the Benjamini-
Hochberg Fdr procedure. We found that the results from adjusted p-values by
Fdr (Benjamini and Hochberg, 1995) and adaptive Fdr (Benjamini et al., 2006)
are compatible to one another.
Table 15
Diease10, which depends on the five genes X1-X5, using n = 102. Benjamini-Hochberg Fdr
picked only four genes unless the number of genes is prescreened to 100. Gradient boosting,
in comparison, was able to pick all five genes from a prescreened pool of 2,000 genes.
Method n = 102 patients n = 204 patients
Boosting-1 X1-X4 X1-X5
(6,033 genes) (missed X5) accuracy = 86.3%
Boosting-2 X1-X5 X1-X5
(2,000 genes) Accuracy = 79% accuracy = 86.3%
Fdr-1 X1-X4 X1-X5
(6,300 genes) (missed X5) + 2 other genes
Fdr-2 X1-X4 X1-X5
(2,000 genes) (missed X5) + 6 other genes
Fdr-3 X1-X5 X1-X5
(100 genes) +1 other gene
Table 15 shows that if n = 204, then both gradient boosting and the Benjamini-
Hochberg Fdr procedure would be able to pick up all important genes. Note that
microarray experiments are very expensive (although the price is decreasing in
recent years), and a large sample like n = 204 may be beyond the reach of many
scientists. Consequently a procedure that can handle small sample is highly
desired.
Turning to the case when n = 102 patients, both gradient boosting and
Fdr missed one important gene, which is not acceptable to biologists - once an
important gene is lost, then it cannot be recovered. Nevertheless, if the number
of the genes is cut from 6,033 to 2,000 using a pre-screening method, then
boosting would succeed, but this is not the case with Fdr. The problem with
Fdr persisted when we cut the number of genes to 500 (not shown in Table 16).
But if the number of genes is cut to 100, then Fdr would succeed.
Gradient boosting is well-known for being able to model nonlinear phenomena
(Friedman, 2001, Annals of Statistics), but if there are too many genes in the
model (e.g., 6,033 genes, too much noise) and n is relatively small (e.g., 102
patients), then the model would fail. For this reason, in Table 15, we use gradient
boosting to rank the predictors, cut the bottom ones and then re-fit the model.
This procedure may raise eyebrows if we do it with Fdr (where p-values are
involved) and one may argue that the repeated adjustments of p-values would
violate the validity of statistical inference. In our opinion, both gradient boosting
and Fdr are exploratory tools in the gene selection, and hence the issue of
statistical inference does not really matter.
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4.3. Ten important genes, n = 102, 204, 306, or 408 patients
We now extend our simulation to include 10 important genes:
f11 =
{
1, if Π10i=1Xi > c11
0, otherwise
The results are shown in Table 16 below.
Table 16
Ten important genes causing Disease 11. In each cell, we give the number of important
genes selected by the specified statistical method, and “. . .” indicates a set of irrelevant
genes were also chosen. We only give data for False Discovery and accuracy when the
statistical method succeeded at finding all 10 relevant genes. We do this because FNDs
(False Non-Discoveries) are not acceptable: once an important gene is lost, then it cannot
be recovered. Note that PLS is not consistent.
n = 102 n = 204 n = 306 n = 408
Boosting-1 1 gene 6 genes 8 genes 9 genes
(6,033 genes) + . . . + . . . + . . . + . . .
Boosting-2 4 genes 9 genes 10 genes 10 genes
(500 genes) + . . . + . . . FDiscovery = 98% FDiscovery = 98%
accuracy = 83% accuracy = 87%
Boosting-3 9 genes 10 genes 10 genes 10 genes
(100 genes) + . . . FDiscovery = 90% FDiscovery = 90% FDiscovery = 90%
accuracy = 80% accuracy = 86% accuracy = 88%
Boosting-4 9 genes 10 genes 10 genes 10 genes
(20 genes) + . . . FDiscovery = 20% FDiscovery = 20% FDiscovery = 20%
accuracy = 87% accuracy = 91% accuracy = 88%
Boosting-5 9 genes 10 genes 10 genes 10 genes
(12 genes) + . . . FDiscovery = 17% FDiscovery = 17% FDiscovery = 17%
accuracy = 88% accuracy = 92.2% accuracy = 94.5%
Fdr 1 gene 5 genes 8 genes 7 genes
(6,033 genes) + X1379 + X1502
Fdr 4 genes 5 genes 7 genes 8 genes
(2,000 genes)
Fdr 4 genes 8 genes 9 genes 10 genes
(500 genes) + X37 + X382
Fdr 4 genes 8 genes 10 genes 10 genes
(100 genes) + X59 + X59
Fdr 5 genes 10 genes 10 genes 10 genes
(20 genes) + X20
PLS-m1 9 genes 9 genes 9 genes 10 genes
(40 genes) FDiscovery = 0%
accuracy = 89%
PLS-m2 9 genes 10 genes 10 genes 9 genes
(20 genes) FDiscovery =0% FDiscovery = 0%
accuracy = 89% accuracy = 89%
The data in Table 16 allows us to readily see the effects of sample size on gene
selection, accuracy and the false discovery rates of various statistical methods.
When looking at ten interacting genes, which can reasonably be expected in
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cancer, a sample size of n = 102 is too small for Fdr, gradient boosting and
PLS, as all important genes are not identified. These false non-discoveries are
costly to biologists, as once a gene is screened out of a pool, there is no chance
of identifying that gene as an essential component of a disease.
Increasing the sample size to n = 204 starts to paint a different picture.
All three methods perform better at this sample size. However, in each case, a
prescreening method is required to cut down the number of genes used in the
model. In the case of Fdr and PLS, the prescreened pool of genes must be of size
20 in order to identify all the relevant genes. When the sample size is n = 204
patients, gradient boosting performs consistently well on prescreened pools of
size 100 genes or smaller.
As we increase the sample size, we find that Fdrs performance improves,
with all ten relevant genes for Disease11 being selected from larger prescreened
pools. PLS’s performance also improves with sample size, but does not pick
up all 10 genes when n = 408 patients and there are 20 genes in the model.
Gradient boosting is a consistent performer at larger sample sizes, provided a
prescreening procedure is applied to cut down the pool of 6,033 genes.
However, gradient boosting is well-known for being an algorithm for greedy
function approximation (Friedman, 2001). As a result, the false discovery rate
is relatively high. For instance, in Table 16, Boosting-3 with n = 204 has an
extremely high false discovery rate of 90%. While it is desirable that boosting
identified all 10 relevant genes, this 90% false discovery rate means the boosting
algorithm is technically selecting all 100 prescreened genes. This seems to sug-
gest that boosting is a weak model. However Figure 7 shows that the Variable
Importance scores of the top relevant genes are much higher than the majority
of the other genes, with the exception of exactly one false discovery in the 11
most important genes. Therefore, while boosting is ranking all genes as impor-
tant, it is ranking the top ten genes (the ten relevant genes that determine the
disease state) as significantly more important than essentially all of the other
genes. This chart can thus be used to allow a biologist to cut down the number
of genes without resulting in the emergence of false non-discoveries. This is pre-
cisely how we cut down the size of the prescreened pool of genes in Boosting-4
and Boosting-5 of Table 16.
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Fig 7. Gene score for the top 25 genes for Boosting-3 (Table 16) with n = 204 patients. The
genes implicated in the disease are shown in dark blue and those not implicated in the disease
are shown in light green. In spite of the high Fdiscovery rate of 90%, the eleven genes with
the highest score contain all ten genes that cause the disease.
4.4. Non-Taylor interactions
In the literature, the gene-gene interactions have been modeled using Taylor
polynomials (see, e.g., Park and Hastie, 2008; Assimes et al., 2008; Cordell,
2009). Our results showed that when gene interactions are described by Taylor
polynomials, gradient boosting is a reliable method when coupled with pre-
screening and a sufficiently large sample size. In this section, we explore a num-
ber of non-Taylor interactions with multiple thresholds and determine if the
statistical methods have the same level of success. The diseases explored are:
f101 =
{
1, if X1 > 27 and X2 > 70 and X3 < 220
0, otherwise
f102 =
{
1, if X1 > 23 and X2 > 34 and X3 < 180
0, otherwise
f103 =
{
1, if X1X2 > 300 and X3 < 140
0, otherwise
For Disease101, the thresholds were chosen so that X1 and X2 are more
important than X3. For Disease102, the three genes (X1, X2, X3) have equal
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weights. For Disease103, X1X2 and X3 have equal weights. Table 17 below shows
the results of Fdr, gradient boosting, and PLS models for these three diseases.
Table 17
Non-Taylor interactions with three genes, X1-X3 with n = 102 patients. Fdr fails on
Disease102 and 103. PLS was shown to be inconsistent in Table 16, therefore we do not
present further results for PLS. Gradient boosting appears to be a better tool.
Disease101 Disease102 Disease103
X1 > X2 ≫ X3 X1, X2, X3 have X1*X2 and X3 have
X3 is minor equal weights equal weights
Fdr X1, X2 , X3 X1, X3 X2, X3
(100 genes)
Boosting-1 X1, X2 , . . . X1, X2, X3 , . . . X1, X2, X3 , . . .
(100 genes) FDiscovery = 78% FDiscovery = 60% FDiscovery = 96%
accuracy = 87% accuracy = 93% accuracy = 100%
Boosting-2 X1, X2 , . . . X1, X2, X3 , . . . X1, X2, X3 , . . .
(20 genes) FDiscovery = 90% FDiscovery = 70% FDiscovery = 85%
accuracy = 87% accuracy = 87% accuracy = 93%
Boosting-3 X1, X2 , . . . X1, X2, X3 , . . . X1, X2, X3 , . . .
(10 genes) FDiscovery = 80% FDiscovery = 70% FDiscovery = 70%
accuracy = 87% accuracy = 93% accuracy = 93%
Boosting-4 X1, X2 , X3, . . . X1, X2, X3 , . . . X1, X2, X3 , . . .
(5 genes) FDiscovery = 40% FDiscovery = 40% FDiscovery = 40%
accuracy = 87% accuracy = 93% accuracy = 93%
Boosting-5 X1, X2 , X3 X1, X2, X3 X1, X2, X3
(3 genes) FDiscovery = 0% FDiscovery = 0% FDiscovery = 0%
accuracy = 87% accuracy = 93% accuracy = 93%
PLS X1, X2 , X3 X1, X2 X2, X3
(100 genes) FDiscovery = 0%
accuracy = 90%
From Table 17, we can see that for non-Taylor gene interactions, PLS and Fdr
do not produce reliable results at a sample size of n = 102. However, gradient
boosting continues to prove to be a better tool, as it can well identify the relevant
genes and classify the data at a sample size of 102 when the gene interactions
are non-Taylor.
5. SUPPORT VECTOR MACHINE
In Table 1 (colon cancer data), we presented certain classification results from
the SVM community. Collectively, the results in Table 1 indicate that there is
room for improvement. In this Section, we will discuss our evaluation of the
SVM technology.
Note that given a set of data that is completely separated by a specific thresh-
old such as Disease1 through Disease11 in our simulations, theoretically it is
possible to construct two convex hulls to separate the data (Figure 8),
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Fig 8. Convex hulls of two data sets that are completely separated from each other.
where a convex hull is defined as
C = {
n∑
j=1
λj
−→pj : λj ≥ 0, ∀j,
n∑
j=1
λj = 1}.
Given the 2 convex hulls, one can define support vectors to find optimal
separation of the data as shown in Figure 9.
Fig 9. Optimal separation of two datasets
For nonlinear problems such as Disease10 and Disease 11, the goal of a support
vector machine is to transform the data from the low-dimensional space to a
high-dimensional space and then use a hyper-plane to separate the data (see,
e.g., Hastie, Tibshirani, Friedman, 2011). When there are 6,033 genes, the pre-
diction space is not really “low dimensional,” but a forward-selection process
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starting with a single gene is feasible. Furthermore, if the biological interactions
of certain genes are roughly known, then that piece of knowledge may guide the
statistician to pick a kernel for optimal separation.
In our simulation study, Disease10 uses 5 important genes to create the target
disease; consequently we would expect the SVM technology to achieve 100%
prediction accuracy when all 5 important genes are fed into the model. Table
18 below shows that this is not the case for the four different kernels we tried.
Table 18
Prediction accuracy of four SVM models.
Disease10 with 5 important genes: X1-X5
Accuracy of SVM (10-fold cross-validation)
Kernel n = 102 n = 204 n = 306 n = 408
Linear 89% 94% 93% 90%
Polynomial 85% 92% 96% 90%
RBF 89% 95% 97% 94%
Sigmoid 89% 90% 93% 89%
Table 19 shows the SVM prediction accuracy for Disease11 with 10 important
genes. The results are equally disheartening.
Table 19
Prediction accuracy of four SVM models.
Disease11 with 10 important genes: X1-X10
Accuracy of SVM (10-fold cross-validation)
Kernel n = 102 n = 204 n = 306 n = 408
Linear 77% 90% 88% 82%
Polynomial 81% 86% 86% 84%
RBF 73% 94% 90% 86%
Sigmoid 73% 92% 87% 83%
Table 19 also shows that the increase of sample size from n = 204 to n = 306
or 408 only confounds the model and the result is a decrease of classification
accuracy.
In the SVM literature, there exists a great variety of kernel functions that
can be used to transform nonlinear to linear data. A list of 25 kernels can be
found at (http://crsouza.blogspot.com/2010/03/kernel-functions-for-machine-learning.html).
The kernels include Laplacian kernel, ANOVA kernel, spline kernel, Bessel ker-
nel, Cauchy kernel, chi-square kernel, histogram intersection kernel, generalized
t-student kernel, Bayesian kernel, wavelet kernel, etc. With modifications and
hybridizations, one may be able to generate hundreds or thousands of other
kernels as partially shown in Table 1 of this paper.
It would be interesting to know whether any of new kernels could actually sep-
arate the data in Disease1 through Disease11, Disease101 through Disease103,
and possibly in other cases where gene interactions are nonlinear or non-Taylor.
We do not see an easy way to meet this challenge. But the effort should be
worthwhile and may generate new insights into this important field of statisti-
cal learning.
C. Wang et al./Casual Inference from High-Dimensional Data 30
The same may be true for thousands of new techniques in the field of variable
selection. In modern statistics, the literature on variable selection is vast, com-
plicated, and chaotic. A systematic approach to evaluate these new tools can be
a huge challenge, but it may be able to provide scientists certain guidance on
how to select tools in the important task of variable selection.
6. Discussions and Concluding Remarks
In a 2008 lecture, Stanley Young of NISS (the National Institute of Statistical
Sciences) maintained that
Empirical evidence is that 80-90% of the claims made by epidemiologists are
false; these claims do not replicate when retested under rigorous conditions.
Young’s conclusion was based on the following: findings from top medical re-
search journals, a survey of journal editors from diverse fields of science, and a
finding that of 20 claims coming from observational studies, only one replicated
when tested in NIH funded randomized clinical trials.
In a follow-up article, Young and Karr (2011) further examined 52 claims
from Journal of the American Medical Association, the New England Journal
of Medicine, Journal of the National Cancer Institute, and Archives of Internal
Medicine. The conclusion is that “Any claim coming from an observational study
is most likely to be wrong.”
To the insiders of statistical analysis of cause-and-effect, a lot of false claims
may be avoidable if researchers take note of a motto from Rubin and Holland
(see Holland, 1986):
No Causation Without Manipulation.
The motto, of course, has exceptions even in observational studies. For example,
in astronomy we cannot manipulate any of the relevant quantities, yet predic-
tions in astronomy are often more accurate than those produced by double-blind
randomized controlled experiments.
In the field of gene identification, data from microarray experiments and from
similar settings are in the category of observational studies, although they are
called “experiments” in the broad scientific community. The use of statistical
analysis to determine which gene (or set of genes) is the cause of a specific
disease is often confounded by the following factors:
1. We cannot flip a coin and then assign a patient to have cancer or no cancer.
Consequently the t-tests, p-values, Bonferrani adjustment, and Benjamini-
Hochberg Fdr all lose their footing in the statistical analysis of cause-and-
effect. Another problem with p-values is that “statistical significance” is
not the same as “practical significance” and the p-values can be very
misleading in the gene selection process. Furthermore, our work has shown
that the t-test is not efficient in the detection of non-Taylor interactions.
2. The situation is worse with the regression model or other machine-learning
tools such as neural networks and support vector machines, even if the
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investigators use various randomization techniques on the laboratory an-
imals. Freedman (2008, Statistical Science) pointed out that “Random-
ization Does Not Justify Logistic Regression.” In addition, he questioned
the scientific ground of using logit versus probit or other types of the link
functions in binary regression. Furthermore, in binary regression, often
there are multiple variables on the right-hand side of the equation, and we
simply cannot expect biologists to randomize or manipulate the variables
in the experiment. The same can be said for other models such as partial
least squares, support vector classifier, and gradient boosting.
3. Another problem with the statistical models and the adjusted p-values is
that often a single gene is responsible for the onset of a specific disease.
But when that gene is altered, it may change the expression level of dozens
of other downstream genes. Imagine a gene that is solely responsible for
causing a specific disease; in its active state, the gene releases proteins
and then the expression of 10 or 20 other genes is affected in the process.
Now how do we expect the shuffling of statistical methods to identify the
primary gene and not pick up all the secondary genes instead?
Fortunately, in the area of gene identification, new techniques have been de-
veloped that would confirm to the motto of Rubin and Holland. As one example,
biologists can create knockout organisms in which the function of a particular
gene is shut down. Using these knockouts, a biologist is able to infer the im-
pact of the shut-down gene by studying how organisms with the gene differ from
organisms without the gene. For instance, Fong and colleagues developed knock-
out mice for the fragile histidine triad (FHIT) gene. They discovered that mice
without this gene are more susceptible to carcinogen-induced tumor formation
than those mice that express the gene (Fong et al., 2000).
While experiments like this are incredibly powerful, this approach is not a
feasible way to identify unknown/undetermined genes that cause a particular
disease - there are simply too many genes in the genome for a biologist to
knock them all out and observe their effect. Statistical analysis of microarray
data reduces this large pool of genes to a reasonably-sized pool that biologists
could then examine using more rigorous experimental approaches. Therefore,
statistical analysis of microarray data can be viewed as an important first step
in identifying genes that potentially cause a particular disease.
In this study, we found that the technique of stochastic gradient boosting
(Freeman, 2001) was able to identify all important genes from a pool of 6,033
with the sample size of n = 102. We did this with simulation datasets that
involve 5-gene interactions, 10-gene interactions and non-Taylor 3-gene interac-
tions. The simulations have been crafted to match the real situation as closely
as possible (Section 3) - the equations are deterministic but they also mimic
the colon cancer data and the prostate cancer data (Efron, 2010, 2008): random
elements, correlations among the genes, etc. In all cases, the gradient boosting
was able to pick the contributing genes.
In comparison, the following techniques missed important genes in various
scenarios: Bonferrani adjustment, Benjamini-Hochberg Fdr, logistic regression,
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partial least squares, LASSO (least angle regression), neural network, decision
tree, and support vector machine. This is problematic and points to the crucial
distinction between false discovery and false non-discovery in the statistical
gene search, where false discovery leads to the selection of irrelevant genes and
false non-discovery misses out important genes that cannot be recovered in the
subsequent analysis. From the biological view point, false non-discovery is not
acceptable for the very reason that if an important gene is lost in the statistical
exploration, then it will mislead subsequent research efforts.
In addition, our investigation shows that commonly used measures in binary
classifications can be very misleading in gene identification: error rate, false
positive, false negative, and other measures that are derived from these values
(sensitivity, specificity, ROC curves, the area under the ROC curve, F -measures,
precision, recall, etc.). The most troubling is that some commonly used models
would produce 100% accuracy measures and select different sets of genes. They
simply cannot stand the scrutiny of parameter estimates and model stability.
Currently there are thousands of tools for variable selection, with new ones
showing up at an exponential rate. The growth of this field will provide us new
techniques to tackle many hard problems with high-dimensional data. Neverthe-
less, the growth also creates a problem for scientists who are facing thousands of
variables and thousands of tools to select the relevant variables. In most cases,
nobody knows which variable is causing what and existing subject knowledge
often conflicts with each other. In many cases, the search process is like trying
to find a black cat in a dark house.
In our investigation, we compared the results from real-world data and from
simulation studies. The use of simulation is a standard practice in statistics, even
college students know that Ulam and von Newmann did it in the Manhattan
Project some 70 years ago. But in the fields of gene search and variable selection,
the literature is very shy on this technology. Here you play god, create the genes
of your liking, investigate the sample size needed, compare the tools, and finally
select the top variables for the specific phenomenon under the study. In our
case, we found that certain widely used models (neural network, PLS, logistic
regression, and LASSO) would render 100% prediction accuracy with genes that
are not responsible for our simulated diseases. On the other hand, with moderate
sample size, gradient boosting will be shown to be a superior model for gene
selection, though we suspect there are more tools that are appropriate for gene
search. We believe a platform would be beneficial in helping to select the top
tools before we try to select the top variables.
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